Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis

Podobne zapisy

• Baricitinib versus placebo or adalimumab in rheumatoid arthritis
  od: Taylor, P, i wsp.
  Wydane: (2017)
• Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
  od: Fautrel, B, i wsp.
  Wydane: (2017)
• Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
  od: Taylor, P, i wsp.
  Wydane: (2017)
• Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
  od: Tanaka, Y, i wsp.
  Wydane: (2019)
• Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
  od: Fautrel, B, i wsp.
  Wydane: (2019)